| Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (NCT02143414) | National Cancer Institute (NCI) | 2015-06-30 |
| Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... (NCT02484404) | National Cancer Institute (NCI) | 2015-06-29 |
| In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma (NCT02489266) | National Cancer Institute (NCI) | 2015-06-24 |
| Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma (NCT02359565) | National Cancer Institute (NCI) | 2015-06-03 |
| PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance (NCT02326805) | National Cancer Institute (NCI) | 2015-06-03 |
| Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer (NCT02430480) | National Cancer Institute (NCI) | 2015-06-03 |
| Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer (NCT02311933) | National Cancer Institute (NCI) | 2015-05-28 |
| Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma (NCT02428192) | National Cancer Institute (NCI) | 2015-05-19 |
| Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors (NCT02423057) | National Cancer Institute (NCI) | 2015-05-18 |
| Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer (NCT02257528) | National Cancer Institute (NCI) | 2015-05-18 |
| Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer (NCT02314169) | National Cancer Institute (NCI) | 2015-05-13 |
| Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139 (NCT02362464) | National Cancer Institute (NCI) | 2015-05-12 |
| Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... (NCT02390752) | National Cancer Institute (NCI) | 2015-04-29 |
| Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma (NCT02311920) | National Cancer Institute (NCI) | 2015-04-16 |
| Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer (NCT02408887) | National Cancer Institute (NCI) | 2015-04-15 |
| Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors (NCT02379416) | National Cancer Institute (NCI) | 2015-04-13 |
| Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (NCT02298959) | National Cancer Institute (NCI) | 2015-04-08 |
| Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery (NCT02315625) | National Cancer Institute (NCI) | 2015-04-08 |
| AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites (NCT02417753) | National Cancer Institute (NCI) | 2015-04-03 |
| Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02315430) | National Cancer Institute (NCI) | 2015-04-01 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (NCT02304458) | National Cancer Institute (NCI) | 2015-03-30 |
| Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer (NCT02311361) | National Cancer Institute (NCI) | 2015-03-25 |
| Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (NCT02166463) | National Cancer Institute (NCI) | 2015-03-19 |
| Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer (NCT02390739) | National Cancer Institute (NCI) | 2015-03-02 |
| BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment (NCT02326844) | National Cancer Institute (NCI) | 2015-03-02 |
| Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) (NCT02193282) | National Cancer Institute (NCI) | 2015-02-11 |
| Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors (NCT02143401) | National Cancer Institute (NCI) | 2015-01-30 |
| A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer (NCT02203513) | National Cancer Institute (NCI) | 2015-01-20 |
| Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials (NCT02315599) | National Cancer Institute (NCI) | 2014-12-23 |
| Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care Treatment (NCT02326857) | National Cancer Institute (NCI) | 2014-12-23 |
| Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD (NCT02322190) | National Cancer Institute (NCI) | 2014-12-20 |
| Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma (NCT02243605) | National Cancer Institute (NCI) | 2014-12-19 |
| Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (NCT02101853) | National Cancer Institute (NCI) | 2014-12-17 |
| Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (NCT02152982) | National Cancer Institute (NCI) | 2014-12-15 |
| Self-Affirmation and Defensiveness to Health Messages for the Self vs. a Close Other (NCT02317380) | National Cancer Institute (NCI) | 2014-12-13 |
| Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (NCT02306161) | National Cancer Institute (NCI) | 2014-12-12 |
| Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies (NCT02315612) | National Cancer Institute (NCI) | 2014-12-12 |
| Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery (NCT02178241) | National Cancer Institute (NCI) | 2014-12-11 |
| Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT02101944) | National Cancer Institute (NCI) | 2014-12-09 |
| Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 (NCT02211768) | National Cancer Institute (NCI) | 2014-12-08 |
| Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas (NCT02192541) | National Cancer Institute (NCI) | 2014-12-02 |
| Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer (NCT02267603) | National Cancer Institute (NCI) | 2014-11-25 |
| Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver (NCT02273362) | National Cancer Institute (NCI) | 2014-11-24 |
| Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients With Subsolid Lung Nodules (NCT02169271) | National Cancer Institute (NCI) | 2014-11-21 |
| AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer (NCT02298946) | National Cancer Institute (NCI) | 2014-11-21 |
| Self-Affirmation, Emotion, and Alcohol Consumption (NCT02311400) | National Cancer Institute (NCI) | 2014-11-19 |
| T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer (NCT02133196) | National Cancer Institute (NCI) | 2014-10-23 |
| Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome (NCT02243579) | National Cancer Institute (NCI) | 2014-10-15 |
| T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers (NCT02280811) | National Cancer Institute (NCI) | 2014-10-14 |
| Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors (NCT02211755) | National Cancer Institute (NCI) | 2014-10-06 |
| Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (NCT02112916) | National Cancer Institute (NCI) | 2014-10-04 |
| Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery (NCT02169284) | National Cancer Institute (NCI) | 2014-10-01 |
| Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NCT02194738) | National Cancer Institute (NCI) | 2014-09-26 |
| Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment (NCT02243592) | National Cancer Institute (NCI) | 2014-09-24 |
| Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread (NCT02196181) | National Cancer Institute (NCI) | 2014-09-19 |
| Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (NCT02219737) | National Cancer Institute (NCI) | 2014-09-12 |
| Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum (NCT02054104) | National Cancer Institute (NCI) | 2014-09-03 |
| Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors (NCT02233842) | National Cancer Institute (NCI) | 2014-09-01 |
| Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection (NCT02109224) | National Cancer Institute (NCI) | 2014-09-01 |
| Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer (NCT02188264) | National Cancer Institute (NCI) | 2014-08-29 |
| Comparison of Two Dose Assessment Methods for Exposures to Nuclear Detonation Radiation (NCT02226874) | National Cancer Institute (NCI) | 2014-08-26 |
| Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02042430) | National Cancer Institute (NCI) | 2014-08-25 |
| Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors (NCT02153957) | National Cancer Institute (NCI) | 2014-08-21 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery (NCT02194829) | National Cancer Institute (NCI) | 2014-08-19 |
| Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (NCT02228512) | National Cancer Institute (NCI) | 2014-08-15 |
| Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer (NCT02152995) | National Cancer Institute (NCI) | 2014-08-14 |
| Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma (NCT02203526) | National Cancer Institute (NCI) | 2014-08-14 |
| Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma (NCT02159755) | National Cancer Institute (NCI) | 2014-08-13 |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery (NCT02180867) | National Cancer Institute (NCI) | 2014-08-12 |
| Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma (NCT02215967) | National Cancer Institute (NCI) | 2014-08-12 |
| Study of Diets and Way of Life of Native Americans and Hispanics in New Mexico During the Time of the Trinity Nuclear Test (NCT02211781) | National Cancer Institute (NCI) | 2014-08-01 |
| Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma (NCT02097238) | National Cancer Institute (NCI) | 2014-08-01 |
| Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity (NCT02154022) | National Cancer Institute (NCI) | 2014-07-31 |
| Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT02101775) | National Cancer Institute (NCI) | 2014-07-21 |
| 18F-DCFBC PET/CT in Prostate Cancer (NCT02190279) | National Cancer Institute (NCI) | 2014-07-12 |
| T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive (NCT02153905) | National Cancer Institute (NCI) | 2014-07-03 |
| Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma (NCT02133183) | National Cancer Institute (NCI) | 2014-07-02 |
| Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection (NCT02134886) | National Cancer Institute (NCI) | 2014-07-01 |
| Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM) (NCT02179515) | National Cancer Institute (NCI) | 2014-06-28 |
| Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps (NCT02134925) | National Cancer Institute (NCI) | 2014-06-23 |
| Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02101918) | National Cancer Institute (NCI) | 2014-06-18 |
| Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02159989) | National Cancer Institute (NCI) | 2014-06-18 |
| Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers (NCT02123849) | National Cancer Institute (NCI) | 2014-06-01 |
| Internet Support Group for Parents of a Child With Neurofibromatosis Type 1 (NCT02153931) | National Cancer Institute (NCI) | 2014-05-31 |
| Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy (NCT02153918) | National Cancer Institute (NCI) | 2014-05-31 |
| Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02097225) | National Cancer Institute (NCI) | 2014-05-29 |
| Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors (NCT02146170) | National Cancer Institute (NCI) | 2014-05-28 |
| TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors (NCT02142803) | National Cancer Institute (NCI) | 2014-05-20 |
| Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (NCT02160015) | National Cancer Institute (NCI) | 2014-05-20 |
| Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (NCT02003222) | National Cancer Institute (NCI) | 2014-05-19 |
| Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies (NCT02116777) | National Cancer Institute (NCI) | 2014-05-16 |
| Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers (NCT02141490) | National Cancer Institute (NCI) | 2014-05-15 |
| Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance (NCT02095145) | National Cancer Institute (NCI) | 2014-05-08 |
| Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases (NCT02015117) | National Cancer Institute (NCI) | 2014-04-28 |
| Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (NCT02101788) | National Cancer Institute (NCI) | 2014-04-11 |
| A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma (NCT02129075) | National Cancer Institute (NCI) | 2014-04-09 |
| Study of Voicing My CHOiCES as a Tool for Advanced Care Planning in Young Adults With Cancer (NCT02108028) | National Cancer Institute (NCI) | 2014-04-03 |
| Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (NCT02129062) | National Cancer Institute (NCI) | 2014-04-01 |
| Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic (NCT02115282) | National Cancer Institute (NCI) | 2014-03-29 |
| Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors (NCT02095132) | National Cancer Institute (NCI) | 2014-03-28 |